medigraphic.com
ISSN 1995-9494 (Electronic)
Revista del Hospital Clínico Quirúrgico "Arnaldo Milián Castro"

2019, Number 3

<< Back Next >>

Acta Med Cent 2019; 13 (3)

Susceptibilidad de cepas de Mycobacterium tuberculosis frente a drogas antimicobacterianas

Rivero PYF

Language: Spanish
References: 14
Page: 297-303
PDF size: 151.31 Kb.


ABSTRACT

Introduction: the infections caused by the Mycobacterium tuberculosis complex are the first cause of death by an infectious agent; in recent years there has been the emergence and dissemination of strains resistant to multiple antimicobacterial drugs. Objective: to determine the susceptibility patterns of strains of Mycobacterium tuberculosis isolated in patients of the Villa Clara Province. Method: a retrospective descriptive study including 116 strains of Mycobacterium tuberculosis isolated in Villa Clara patients from July 2015 to July 2018 was carried out with susceptibility tests performed by the nitrate reductase method, the proportions method and molecular methods. Results: sensitivity to isoniazid and rifampicin was found in 105 strains, four multidrug-resistant strains were found, as well as one extremely resistant strain. Conclusions: Mycobacterium tuberculosis strains in Villa Clara Province mostly show sensitivity patterns, a small number is multidrug-resistant and the number of extremely resistant strains is negligible. The recognition of the low prevalence of these last patterns is a tool for the control of their dissemination in the province.


REFERENCES

  1. Alcaide Fernández de Vega F, Esteban Moreno J, González Martín J, Palacios Gutiérrez JJ. Procedimientos en Microbiología Clínica. Recomendaciones de la Sociedad Española de Enfermedades Infecciosas y Mocrobiología Clínica. Micobacterias 9a. [Internet]. Madrid: Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC); 2005 [citado 26 May 2018]. Disponible en: https://www.seimc.org/contenidos/documentoscientificos/procedimientosmicrobiologia/seimc-procedimientomicrobiologia9a.pdf

  2. World Health Organization. Global tuberculosis control: WHO report 2017 [Internet]. Geneva: World Health Organization; 2018 [citado 26 May 2018]. Disponible en: https://www.who.int/tb/publications/global_report/gtbr2018_main_text_28Feb2019.pdf?ua=1

  3. Ministerio de Salud Pública. Dirección Nacional de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud 2017 [Internet]. La Habana: Minsap; 2018 [citado 26 May 2018]. Disponible en: http://files.sld.cu/dne/files/2018/04/Anuario-Electronico-Espa%C3%B1ol-2017-ed-2018.pdf

  4. Lemus Molina D. Métodos rápidos para la detección de resistencia en Mycobacterium tuberculosis [tesis doctoral]. La Habana: Instituto de Medicina Tropical Pedro Kourí; 2007 [citado 24 Abr 2016]. Disponible en: http://tesis.sld.cu/index.php?P=FullRecord&ID=91

  5. Angeby KA, Klintz L, Hoffner SE. Rapid and inexpensive drug susceptibility testing of Mycobacterium tuberculosis with a nitrate reductase assay. J Clin Microbiol [Internet]. 2002 Feb [citado 24 Abr 2016];40(2):553-5. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/11825971

  6. Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, Mitchison DA, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programs. Bull World Health Organ [Internet]. 1969 [citado 24 Abr 2016];41(1):21-43. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427409/

  7. Hain Lifescience [Internet]. Nehren (DE): Hain Lifescience GmbH. Products. Genotype® MTBDRplus VER 2.0 – Your test system for a fast and reliable way to detect MDR-TB [citado 24 Apr 2016]. 2015 [aprox. 1 pantalla]. Disponible en: https://www.hain-lifescience.de/en/products/microbiology/mycobacteria/tuberculosis/genotype-mtbdrplus.html

  8. Hain Lifescience [Internet]. Nehren (DE): Hain Lifescience GmbH. Products. Genotype® MTBDRs/ VER 1.0 and VER 2.0 – Your important assistance for detection of XDR-TB. 2016 [citado 24 Abr 2016]:[aprox 1 pantalla]. Disponible en: https://www.hain-lifescience.de/en/products/microbiology/mycobacteria/tuberculosis/genotype-mtbdrsl.html

  9. Heifets LB, Cangelosi GA. Drug susceptibility testing of Mycobacterium tuberculosis a neglected problem at the turn of the century. Int J Tuberc Lung Dis [Internet]. 1999 Jul [citado 24 Abr 2016];3(7):564-81.Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/10423219

  10. 10.Caminero Luna JA. Origen, presente y futuro de las resistencias en tuberculosis. Arch Bronconeumol [Internet]. 2001 [citado 24 Abr 2016];37:35-42.Disponible en: https://www.archbronconeumol.org/es-pdf-S0300289601750053

  11. 11.Palomino JC. Newer diagnostics for tuberculosis and multi-drug resistant tuberculosis. Curr Opin Pulm Med [Internet]. 2006 May [citado 24 Abr 2016];12(3):172-8. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/16582671

  12. 12.Raj Abraham P, Upadhyay P, Faujdar J, Gangane R, Gaddad SM, Sharma Vishnu D, et al. Drug susceptibility profiles of Mycobacterium tuberculosis isolates from Gulbarga, South India. Egyptian Journal of Chest Diseases and Tuberculosis [Internet]. 2015 [citado 24 Abr 2016];64:933–937. Disponible en: https://core.ac.uk/download/pdf/82241561.pdf

  13. 13.Canetti G, Rist N, Grosset J. Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation. Rev Tuberc Pneumol (Paris) [Internet]. 1963 Feb-Mar [citado 26 Jun 2018];27:217-72. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/14018284

  14. 14.Sánchez Chóez J, Granda Pardo JC, Medina Franco S, Kure Segura N, Antepara Sotomayor R. Sensibilidad a drogas de primera línea frente a cepas de M. tuberculosis del CRN Micobacterias, Guayas, 2016. INSPILIP [Internet]. 2018 [citado 26 Jun 2018];2(3):1-9. Disponible en: http://www.inspilip.gob.ec/wp-content/uploads/2019/03/Sensibilidad_drogas_d_-primera_l%C3%ADnea1.pdf




2020     |     www.medigraphic.com